Since the last CCSG renewal, Development Funds have supported 1) the recruitment of ten outstanding early career investigators, 2) development of two new shared resources and implementation of eight new services in existing shared resources, and 3) partial funding for fourteen MD Anderson Multidisciplinary Research Program (MRP) awards. The $500,000 of CCSG support for faculty recruitment has leveraged over $5.0M in MD Anderson start-up packages and more than $29.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of P01, SPORE, and CPRIT multi-investigator grant applications. Since the inception of the program in 1997, MD Anderson has invested $11.2M in MRP grants. These awards have been associated with external peer-reviewed funding of more than $157M, representing a 14.1-fold return on investment. During the present grant cycle, 17 proposals have been supported with $625,000 from CCSG Development Funds matched approximately 5:1 with institutional funds. This investment of CCSG support has leveraged $18.6M in extramural funding to date, with $8.8M from Multi-PI awards and $9.8M from individual investigator awards that resulted from projects supported as part of an MRP. Development Funds supported establishing the Functional Genomics Core (FGC) and the Assessment, Intervention and Measurement (AIM) core. In the current CCSG application, Development Funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for four developing shared resources: the Oncology Research and Immuno-Monitoring Core (ORION), the Microbiome Core Facility, the Shared Decision Making (SDM) Core, and the Metabolomics Core. Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources and to fund collaborative pilot projects within and between programs are also proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-43S1
Application #
9997888
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141

Showing the most recent 10 out of 12418 publications